A recording of our joint webinar "WM and COVID-19" held in partnership with Lymphoma Action on Friday 19th June, is now available for those who were not able to join us on the day, or who wish to watch it again.
Advice for Waldenstrom's macroglobulinaemia (WM) patients from Dr Shirley D’Sa, WMUK trustee and lead WM clinician at UCLH, in response to the Government's plans to ease shielding for people who are shielding in England, from Monday 6 July.
Dr Shirley D'Sa, WMUK Trustee and Consultant Haematologist and WM lead at University College London Hospitals, explains the science behind the current COVID-19 pandemic and what we know about this virus.
The COVID Symptom Tracker developed by ZOE Global Limited, alongside King's College London, to study the symptoms and spread of COVID-19, have now partnered with the UK's leading charities and all of the Royal Medical Colleges, to better understand the virus in those who are more vulnerable. To help support this important initiative, more volunteers are needed to take part.
Research amongst WM patients with COVID-19 shows interesting findings.
There is a suggestion that BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib may provide favourable suppression of the immune system resulting in the reduction of inflammatory damage to the lungs due to COVID-19 - the so-called cytokine release syndrome (CRS).